25,169 Shares in The Chemours Company (NYSE:CC) Acquired by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC has acquired a new stake in The Chemours Company, purchasing 25,169 shares valued at around $341,000 during the 1st quarter.
• Analyst ratings are mixed, with UBS lowering its price target from $18.00 to $17.00 and Goldman Sachs reducing its target from $21.00 to $14.00, while Chemours has a consensus rating of "Hold" at an average price target of $17.38.
• The company recently reported earnings of $0.58 per share, surpassing expectations and showing a 5% increase in quarterly revenue compared to the previous year.

Natixis Advisors LLC acquired a new stake in shares of The Chemours Company (NYSE:CC - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,169 shares of the specialty chemicals company's stock, valued at approximately $341,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of CC. FNY Investment Advisers LLC purchased a new position in Chemours in the first quarter valued at about $27,000. UMB Bank n.a. raised its position in Chemours by 73.9% in the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock worth $30,000 after purchasing an additional 948 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Chemours by 170.7% in the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 1,444 shares in the last quarter. Itau Unibanco Holding S.A. lifted its position in Chemours by 39.3% during the fourth quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock worth $60,000 after acquiring an additional 1,003 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Chemours during the fourth quarter worth $91,000. Institutional investors and hedge funds own 76.26% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. UBS Group dropped their price target on shares of Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Barclays cut their price objective on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 28th. Mizuho upped their price objective on shares of Chemours from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. The Goldman Sachs Group decreased their target price on Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a research note on Wednesday, May 14th. Finally, Royal Bank Of Canada raised their target price on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a research report on Thursday, July 3rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $17.38.

Chemours Price Performance

Shares of NYSE CC traded down $0.48 during mid-day trading on Friday, reaching $14.59. The company had a trading volume of 4,347,227 shares, compared to its average volume of 3,591,315. The business's 50-day simple moving average is $12.50 and its 200 day simple moving average is $13.12. The Chemours Company has a one year low of $9.13 and a one year high of $22.38. The firm has a market cap of $2.18 billion, a price-to-earnings ratio of -5.21 and a beta of 1.61. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%. The business's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.38 EPS. On average, research analysts predict that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be paid a $0.0875 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.4%. Chemours's payout ratio is currently -12.50%.

Insider Transactions at Chemours

In other Chemours news, CEO Denise Dignam bought 4,068 shares of the business's stock in a transaction dated Friday, August 8th. The shares were purchased at an average price of $12.06 per share, with a total value of $49,060.08. Following the completion of the purchase, the chief executive officer owned 191,546 shares in the company, valued at $2,310,044.76. This represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Damian Gumpel acquired 13,400 shares of the stock in a transaction dated Monday, June 2nd. The stock was acquired at an average cost of $9.22 per share, with a total value of $123,548.00. Following the transaction, the insider directly owned 123,879 shares in the company, valued at approximately $1,142,164.38. This represents a 12.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 29,740 shares of company stock worth $300,633 over the last quarter. 0.47% of the stock is currently owned by insiders.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.